NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology. The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.
HT-003 is a group of retinoic acid metabolism blocking agents (RAMBA), which are novel agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body.
As part of the study, mouse skin was topically pre-treated with RAMBA or a non-clinical vehicle for two days. Then, the skin was intradermally injected peptidoglycan (PGN), which induces acne-like inflammation. The models demonstrated that PGN-induction of TLR2 and a broad list of inflammatory cytokines were inhibited in skin pre-treated with RAMBA.
"The results of this study are extremely promising and suggests that this drug could both treat acne and may actually help prevent it," said Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, who is lead on the study. "The data also suggests that the HT-003 compounds have the potential for treatment of numerous inflammatory skin diseases."
In addition to the dermatologic application, Hoth Therapeutics is exploring the potential application of HT-003 assets in inflammatory bowel disorders (IBDs).
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
LR Advisors LLC
Phone: (678) 570-6791
Media Relations Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-confirmatory-results-from-in-vivo-model-of-ht-003-assets-as-potential-treatment-against-acne-301332322.html
SOURCE Hoth Therapeutics, Inc.